Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07706764

A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism

This trial will enroll adolescents between ages of ≥12 and <18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it is. At least 12 participants will receive palopegteriparatide for 234 weeks. This trial will be conducted in Europe.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Ascendis Pharma Investigational Site, Bron, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Males and females, 12 to less than 18 years of age
  • 2. Participants with postsurgical chronic hypoparathyroidism, or auto-immune, genetic, or idiopathic hypoparathyroidism for at least 26 weeks
  • 3. Normal levels of serum 25(OH) vitamin D and magnesium
  • 4. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73
  • 5. Able to perform daily subcutaneous self-injections of palopegteriparatide (or have a caregiver to perform injections)
  • 6. Body mass index (BMI) Z-score greater than -2 SDS and below + 3 SDS
  • 7. Written, signed informed consent

Exclusion criteria

  • 1. Impaired responsiveness to PTH which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
  • 2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than hypoparathyroidism, such as active hyperthyroidism
  • 3. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 µg/day, or systemic corticosteroids (other than as replacement therapy). Short course use of steroids (≤2 weeks/year) equivalent to prednisone ≤60 mg/day is permitted
  • 4. Use of thiazide diuretic
  • 5. Use of PTH-like drugs
  • 6. Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets (>0.5 mg/day), strontium, or cinacalcet hydrochloride, within 12 weeks prior to Screening
  • 7. Use of osteoporosis therapies known to influence calcium and bone metabolism, i.e., bisphosphonate (oral or intravenous [IV]), denosumab, raloxifene, or romosozumab therapies within 2 years prior to Screening
  • 8. Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening
  • 9. Increased risk for osteosarcoma
  • 10. Female participants who are pregnant, intend to become pregnant, or are lactating
  • 11. Diagnosed drug or alcohol dependence within 3 years prior to Screening

Treatment and study plan

Palopegteriparatide

Combination Product

Subcutaneous injection for 234 weeks

Other names: Yorvipath

Primary outcomes

  1. Percentage of participants meeting the multicomponent efficacy endpoint at Week 26

    Time frame: 26 weeks

    The multi-component endpoint is the percentage of participants who met the following criteria at Week 26: 1) albumin-adjusted serum calcium within the normal range ; 2) independence from active vitamin D, and 3) independence from therapeutic doses of calcium

Secondary outcomes

  1. Percentage of participants meeting the multicomponent efficacy endpoint through Week 234

    Time frame: 234 weeks

    The multi-component endpoint is the percentage of participants who met the following criteria: 1) albumin-adjusted serum calcium within the normal range (8.3-10.6 mg/dL) 2) independence from active vitamin D; and 3) independence from therapeutic doses of calcium.

  2. Serum biochemistries

    Time frame: 234 weeks

    Change from baseline and normalization of serum calcium, mmol/L

  3. Serum biochemistries

    Time frame: 234 weeks

    Change from baseline and normalization of serum phosphate, mmol/L

  4. Serum biochemistries

    Time frame: 234 weeks

    Change from baseline and normalization of serum creatinine, mL/min

  5. Renal calcifications

    Time frame: 234 weeks

    Incidence of nephrolithiasis or nephrocalcinosis on renal ultrasound

  6. Hospitalizations/emergency room (ER)/urgent care visits

    Time frame: 234 weeks

    Number of hospitalizations/ER/urgent care visits

  7. Adverse events

    Time frame: 234 weeks

    Percentage of participants experiencing an adverse event

  8. Bone mineral density

    Time frame: 234 weeks

    Bone mineral density measured by dual-energy x-ray absorptiometry (DXA)

  9. Bone turnover marker

    Time frame: 234 weeks

    Qualitative evaluation of bone turnover marker ctx (ng/L) in blood sample

  10. Bone turnover marker

    Time frame: 234 weeks

    Qualitative evaluation of bone turnover marker p1np (ng/mL) in blood sample

  11. HPES-Symptom score

    Time frame: 234 weeks

    Hypoparathyroidism Patient Experience Scale (HPES) Symptom score, including Physical and Cognitive Domains

  12. HPES-Impact score

    Time frame: 234 weeks

    Hypoparathyroidism Patient Experience Scale (HPES) Impact score, including Physical Functioning and Daily Life Domains

  13. Urine biochemistries

    Time frame: 234 weeks

    Urine biochemistries to include 24-hour urine calcium

Study contacts

Contact information is provided by the study sponsor or research team.

Ascendis Registry Inquiries

CONTACT

[email protected]

+45 61242484

Sponsors and collaborators

Lead sponsor

Ascendis Pharma A/S

Industry

Registry information

Official study title

A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) With Chronic Hypoparathyroidism

Important dates

Study start
2026
Primary completion
2027
Study completion
2031
First posted
Jul 16, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.